Israeli Digital Health Innovators Spotlight: Geneformics, GlucoMe, Consumer Physics Among Pioneers Filing IPO

1. Geneformics: Storage and Transmission of Genomic Big Data

Geneformics focuses on the development of big data storage and transmission systems. Its data compression technology can achieve 20-fold lossless compression of genomic data, laying the foundation for the application of big data in this field. Some investors believe that the generalizability of this technology is limited.The company’s founder and CEO is Arik Keshet, who has been operating the company since 2013. An expert in electrical engineering, he previously founded Channelot and served at Gilat Satellite Networks (NASDAQ: GILT) for over two decades.

Speech by Company Founder and CEO Arik Keshet

2. GlucoMe: High-Tech Blood Glucose MeterGlucoMe has developed a mobile healthcare solution for diabetes patients, creating a specialized high-tech glucose meter. Its core function is to transmit monitoring data to the cloud via smartphones or tablets through a specially designed interface, thereby enabling data collection, big data analysis, alert notifications, and optimized patient monitoring. Thanks to technological advancements, this glucose meter boasts exceptional hardware and software reliability along with outstanding cost-effectiveness.Shen Haiyin, Vice President of Qihoo 360, stated, “This glucose monitoring device does not require Wi-Fi, Bluetooth, or data cables; it uses the microphone for data transmission, resulting in low costs and broad applicability.”GlucoMe also ensures that fluctuations in blood glucose levels are not solely the patient’s concern; family members can monitor the patient’s condition in real time through social networking services (SNS). Patients no longer need to make frequent hospital visits, as all necessary care can be managed from home.Dov Moran, the founder of GlucoMe, is himself a diabetes patient. He was diagnosed with type 2 diabetes in 2013 and required daily blood glucose monitoring. At that time, conventional glucose meters operated in isolation: after testing, no one else knew the results, and there was often no record even confirming whether a test had been performed.Those familiar with the venture capital community know Dov Moran well. Known as the father of the USB flash drive, he sold M-Systems to SanDisk for $1.6 billion in 2006. He is also one of the key promoters of Israel’s high-tech venture capital sector. As a renowned serial entrepreneur, he has invested in more than 15 startups and holds over 40 technical patents.He currently serves as a managing partner at the Israeli venture capital and private equity firm Grove Ventures, and also manages Comigo and Consumer Physics.

GlucoMe’s Founder, Dov Moran

3. Consumer Physics: Palm-Sized Molecular Sensor—SCiO

They have developed a palm-sized molecular sensor—SCiO. This miniature sensor can rapidly analyze the chemical composition of any nearby object, such as food, pharmaceuticals, and plants, with results displayed on a smartphone. The device offers users a seamless, lightning-fast experience that is non-invasive and contactless; simply pressing a switch completes the process.Spectrometers are typically used for high-end near-infrared spectral analysis, a technology with a century-long history. Traditional equipment is large and expensive, with laptop-sized machines costing tens of thousands of dollars. SCiO’s success lies in its significant miniaturization and cost reduction, bringing it to the level of an ordinary consumer product.Consumer Physics has completed multiple rounds of financing, including crowdfunding on Kickstarter and several rounds of venture capital and private equity investment. The company offers partial permanent free services to crowdfunding supporters. Subsequent platform development has attracted a large number of developers to jointly build the SCiO ecosystem, including backend software development for Android and iOS mobile applications and the development of molecular sensing models. The platform provides a Software Development Kit (SDK) for developers.The development of Consumer Physics encompasses a vast network involving the Internet of Things (IoT), cloud computing, metadata, data analytics, and machine learning. Regarding algorithm-based approaches, the larger the volume and scope of data, the more reliable the results. In the future, the platform will collaborate with developers to expand into more applications, such as step-by-step beer brewing and plastic sorting for recycling.Consumer Physics has two co-founders. Dror Sharon is the company’s CEO; he previously served as CEO of the optoelectronic products company OPGAL and was responsible for business development at ColorChip. The other founder, Damian Goldring, holds a Ph.D. in electro-optical materials and nanophotonics.4. Medicope: Cancer Insights from Those Who Have “Been There”

Sometimes, despite undergoing scientific and standardized treatment, cancer patients may ultimately survive for reasons unrelated to the disease itself, however minor they may be.Medicope, a digital companion mobile application, is specifically developed for patients with chronic and serious illnesses. It aims to provide patients and their caregivers with structured, phase-specific clinical and, particularly, non-clinical insights, advice, and emotional support. The key focus is that, beyond the conventional treatments prescribed by doctors, much of the guidance comes from survivors who have “been there.” Because overcoming illness is a long journey, countless patients falter due to non-clinical factors such as emotional distress and overlooked details.Through Medicope, users can accurately identify the decisive factors influencing the recovery process at the most critical junctures, thereby empowering patients and their caregivers with greater confidence in managing the disease. For instance, slight adjustments to nutritional plans have alleviated severe nausea in some patients; users can also learn which expenditure structures offer better cost-effectiveness, and which efforts yield the greatest results at different pathological stages of malignant tumors. Some survivors even remark, “If only I had received such advice back then.”There is a concrete plan to realize this vision. Medicope has already launched its “Insight Mapping” feature, which can be likened to a surveying project. Each patient generates a personal timeline, with nodes representing different insights distributed along it. Once uploaded, these data form a database that ultimately evolves into an easy-to-use advisory system, allowing real-time sharing among users.The founding team of Medicope was established in 2014, with all founders having lost close relatives to cancer. The company’s CEO, Boaz Gaon, lost his father—who served as President of the Israel Cancer Association—to malignant kidney cancer. Despite having access to top-tier medical resources, his father succumbed to unpredictable factors. Having assisted many similar patients, Boaz Gaon is committed to building a company dedicated to patient navigation.Arik Gilon serves as the COO, overseeing product development. He brings over 20 years of executive experience in high-tech companies. Jonathan Engel heads business operations and development while also advising several startups. Arie Gofer is the CTO, leading research and development. He has more than 25 years of experience across the entire operational chain in software and mobile technology.Earlier this year, Medicope was accepted into the Microsoft Accelerator program. Microsoft runs one of the world’s most successful accelerator programs, with six branches globally, including one in Tel Aviv.5. MediSafe: Optimizing the Healthcare Ecosystem Through Medication Reminders

MediSafe is a cloud-synced medication reminder application that helps patients, their families, and caregivers easily manage complex medication regimens in real time.Studies show that due to patient negligence and the inherent complexity of pharmacotherapy, average medication adherence for chronic disease treatment is only 50%. Patients often fail to strictly follow medical advice, resulting in suboptimal therapeutic outcomes. This not only increases the burden on health insurance systems but also causes financial losses for pharmaceutical manufacturers and insurers.MediSafe was developed to address a range of issues caused by careless medication management (preliminary statistics estimate the resulting economic loss at $290 billion annually). MediSafe consolidates all medications into a single mobile interface, allowing users to add drugs simply by scanning the barcode on the packaging with their camera. Its dashboard-style main interface provides an at-a-glance view of medications scheduled for each time slot. Family members’ medication lists can be merged to enable mutual reminders. The app features alerts for refilling prescriptions and medication expiration dates, and medication adherence data can be exported to Excel format with one click for physicians to track and reference. According to MediSafe’s data, its users’ medication adherence rate has reached 86%.In addition to the patient-facing mobile app (compatible with Android and iOS smartphones and tablets), the software offers enterprise versions for pharmaceutical companies, pharmacies, hospitals, and suppliers. Furthermore, considering various factors, the service supports “non-smartphone” functionality: reminders can still be delivered via automated phone calls and SMS services.All big data is automatically backed up and secured on MediSafe’s cloud servers, which are HIPAA-compliant. Currently, MediSafe has been selected as a partner by IMS Health, a global healthcare data management company. By combining MediSafe’s typical, fully characterized de-identified data (covering conditions such as diabetes, heart disease, and cancer) with IMS Health’s comprehensive database, algorithms and analytics will provide market research and decision support for healthcare policymakers and stakeholders.MediSafe was founded in 2012 by Omri “Bob” Shor. The idea for the company originated when his father, who suffered from diabetes, was admitted to the intensive care unit after accidentally administering a double dose of insulin. Shor hoped this software would help reduce hospitalization and mortality rates among patients.MediSafe currently maintains offices in Boston and Israel. Since its inception, the company has won numerous startup awards, including the Grand Prize at the 2014 Qualcomm QPrize Global Startup Competition.6. Medivizor: The Think Tank for Patients with Critical and Chronic IllnessesMedivizor is an information retrieval software built on a basic architecture of a mobile application integrated with a social network. It was developed specifically for patients suffering from serious and chronic diseases. Due to the complex and highly individualized nature of these conditions, many patients attempt to find useful results through online searches but often fail. This is because targeted, and even proactive, information and therapies are not publicly accessible and are frequently difficult to understand.While Medivizor’s basic services are free, it also offers premium paid subscriptions. The platform provides highly personalized medical information, including cutting-edge medical technological discoveries, frontier research, clinical trials, medical guidelines, and lifestyle recommendations. Medivizor tackles the daunting task of finding a needle in a haystack by ensuring that this information meets three critical criteria for patients: high relevance, readability, and applicability. Medivizor leverages its technology to fulfill these requirements.Medivizor sources its information from professional online medical publications, the latest research, new therapies, and relevant medical institutions and experts. The Medivizor platform is currently in public beta testing and supports information retrieval for several complex conditions associated with major diseases. It addresses 88% of cancer-related information needs, including breast cancer, prostate cancer, colorectal cancer, lung cancer, and melanoma. It meets 75% of the information needs for cardiovascular diseases, including hypertension, coronary artery disease, heart disease, myocardial infarction, and stroke. The platform also achieves a 75% match rate for inquiries related to infertility and rheumatoid arthritis.Medivizor delivers information to patients in plain language, a significant challenge given the obscurity of typical medical literature. It is precisely for this reason that The Huffington Post has recommended the Medivizor app.Founded in 2012, Medivizor has grown to become one of Israel’s top ten most promising healthcare internet projects. The company’s President is Dr. Oren Fuerst, a seasoned entrepreneur, investor, and inventor whose many ideas have been commercialized by large healthcare corporations. The CEO is Tal Givoly, who brings over 25 years of experience in software and product R&D management. His career is marked by the label “vision implementer,” renowned for realizing corporate dreams, including those of startups. The expert advisory team includes specialists in urology, breast surgery, pediatric cardiology, and women’s heart health, as well as clinical professors and experts in diabetes and gastroenterology.

Tal Givoly, CEO of Medivizor

7. MedAware: Eliminating Prescription ErrorsMedAware provides innovative solutions to mitigate a range of issues caused by prescription errors, saving patients’ lives, improving safety conditions, and significantly reducing healthcare costs. The platform identifies prescription errors in real time.In the United States alone, prescription errors cause between 200,000 and 400,000 premature deaths annually, with direct losses exceeding $21 billion. Among the 4 billion well-documented prescriptions, 8 million contain errors, primarily involving drug interactions, dosage, and allergies.MedAware’s technology leverages big data analytics and machine learning algorithms to analyze vast amounts of electronic health record (EHR) data, automatically identifying how physicians make errors in real-world clinical scenarios. The application offers a suite of early warning and risk management tools designed to specifically enhance patient safety and the quality of healthcare.MedAware was founded in 2012. Its co-founder and CEO is Gidi Stein, who holds a Ph.D. in computational biology and is a licensed physician, software engineer, and entrepreneur. With over 20 years of experience in the IT industry, he has served as chief architect for several IT-driven startups.

MedAare Co-founder and CEO Gidi Stein Shares Insights with VCBeat Readers

 Note: This series of special topics is provided by Intour, and the related translation was completed by Liu Tianyong, a special correspondent for VCBeat.